Loading
FX-111 is an experimental protein degrader from Flare Therapeutics, in phase 1 trials for metastatic castration-resistant prostate cancer.
FX-111 is a degrader (the company describes its molecules as small molecules) from Flare Therapeutics. A selective degrader of the active, hormone-bound form of the androgen receptor, which the company calls AR ON. The phase 1 study NCT07719361, which started in July 2026, is recruiting. Whether it works in people has not been established.
A selective degrader of the active, hormone-bound form of the androgen receptor, which the company calls AR ON. Connects to Androgen receptor.
1.FX-111 binds Androgen receptor with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FX-111" OR ABSTRACT:"FX-111") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FX-111, not a curated reading list.
Shares Flare Therapeutics and the tag pipeline.
Shares Androgen receptor, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Flare Therapeutics and the tag pipeline.
Shares Androgen receptor, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/